title: Aminopyrimidines with high affinity for both serotonin and dopamine receptors.
abstract: A series of [4-[2(4-arylpiperazin-1-yl)alkyl]cyclohexyl]pyrimidin-2-ylamine s was prepared and found to have receptor binding affinity for D2 and D3 dopamine (DA) receptors and serotonin 5-HT1A receptors. The structural contributions to D2/D3 and 5-HT1A receptor binding of the aminopyrimidine, cycloalkyl, and phenylpiperazine portions of the molecule were examined. From these studies compounds 14, 39, 42, 43, having potent affinity for both DA D2 and 5-HT1A receptors, were evaluated for intrinsic activity at these receptors, in vitro and in vivo. Compound 14 (PD 158771) had a profile indicative of partial agonist activity at both D2 and 5-HT1A receptors causing partially decreased synthesis of the neurotransmitters DA and 5-HT and their metabolites. This compound has a profile in behavioral tests that is predictive of antipsychotic activity, suggesting that mixed partial agonists such as 14 may have utility as antipsychotic agents with increased efficacy and decreased side effects.
authors.affiliation: Department of Chemistry, Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company, Ann Arbor, Michigan 48105, USA.
authors.forename: D
authors.initials: D
authors.lastname: Wustrow
authors.forename: T
authors.initials: T
authors.lastname: Belliotti
authors.forename: S
authors.initials: S
authors.lastname: Glase
authors.forename: S R
authors.initials: SR
authors.lastname: Kesten
authors.forename: D
authors.initials: D
authors.lastname: Johnson
authors.forename: N
authors.initials: N
authors.lastname: Colbry
authors.forename: R
authors.initials: R
authors.lastname: Rubin
authors.forename: A
authors.initials: A
authors.lastname: Blackburn
authors.forename: H
authors.initials: H
authors.lastname: Akunne
authors.forename: A
authors.initials: A
authors.lastname: Corbin
authors.forename: M D
authors.initials: MD
authors.lastname: Davis
authors.forename: L
authors.initials: L
authors.lastname: Georgic
authors.forename: S
authors.initials: S
authors.lastname: Whetzel
authors.forename: K
authors.initials: K
authors.lastname: Zoski
authors.forename: T
authors.initials: T
authors.lastname: Heffner
authors.forename: T
authors.initials: T
authors.lastname: Pugsley
authors.forename: L
authors.initials: L
authors.lastname: Wise
mesh_terms: D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D018360:Crystallography, X-Ray; D006801:Humans; D008297:Male; D051379:Mice; D008968:Molecular Conformation; D015394:Molecular Structure; D010879:Piperazines / Q000138:chemical synthesis* / Q000737:chemistry / Q000378:metabolism*; D011743:Pyrimidines / Q000138:chemical synthesis* / Q000737:chemistry / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011954:Receptors, Dopamine / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D050637:Receptors, Dopamine D3; D011985:Receptors, Serotonin / Q000378:metabolism*; D011994:Recombinant Proteins / Q000378:metabolism; D012453:Saimiri; D013329:Structure-Activity Relationship
chemical_list: C493593:DRD3 protein, human; C493594:Drd3 protein, mouse; C493595:Drd3 protein, rat; C111318:PD 158771; D010879:Piperazines; D011743:Pyrimidines; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D011985:Receptors, Serotonin; D011994:Recombinant Proteins